检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]徐州医学院附属淮安医院眼科,江苏淮安223002
出 处:《山东大学耳鼻喉眼学报》2013年第2期75-76,80,共3页Journal of Otolaryngology and Ophthalmology of Shandong University
摘 要:目的探讨早期激光联合曲安奈德治疗视网膜颞上支静脉阻塞继发黄斑水肿的临床疗效。方法经FFA、OCT检查确诊为视网膜颞上支静脉阻塞继发黄斑水肿的患者42例(42眼),经球旁注射曲安奈德及倍频YAG532激光机进行早期视网膜激光光凝,光凝术后1、3、6个月观察视力、眼压、FFA、黄斑中心凹视网膜厚度。结果治疗后6个月视力增加37例,不变4例,减退1例。治疗前最佳矫正视力>0.3者11例,治疗后23例。治疗前CMT为(561±104)μm,治疗后6个月为(349±93)μm,差异有统计学意义(P<0.01)。球周注射曲安奈德后1、3、6个月分别有2、6、1眼眼压增高,滴用降眼压药水后均能控制。结论早期激光联合球周注射曲安奈德可安全有效地治疗视网膜颞上支静脉阻塞继发黄斑水肿。Objective To evaluate the effect of early laser photocoagulation combined with triamcinolone acetonide (TA) in treating macular edema secondary to temparal branch retinal vein occlusion. Methods A total of 42 patients (42 eyes) with macular edema secondary to temparal branch retinal vein occlusion diagnosed by fundus fluorescein an- giography(FFA) and optical coherence tomography (OCT) were treated by TA and early laser photocoagulation. The changes were observed including the visual acuity, intraocular pressure, FFA and CMT in the first, third and sixth months after treatment. Results The visual acuity 6 months after treatment was improved in 37 eyes, remained the same in 4 eyes, and declined in 1 eye. The best corrected visual acuity was more than 0.3 in 11 eyes before treatment and 23 eyes after treatment. The CMT was (561± 104)μm before treatment, and(349±93) μm 6 months after treat- ment (P 〈 0.01 ). The introaocular pressure increased in 2, 6 and 1 eyes 1, 3 and 6 months after treatment respective- ly, and became normal after eye drops administration for a short time. Conclusions Early laser photocoagulation com- bined with retrobulbar injection of TA is safety and effective in treating macular edema secondary to temparal branch ret- inal vein occlusion.
关 键 词:曲安奈德 视网膜颞上支静脉阻塞 黄斑水肿 激光光凝
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.28